Healthcare >> CEO Interviews >> April 9, 2014
Dr. Bernd Liesenfeld is President of Quick-Med Technologies, Inc. Dr. Liesenfeld joined Quick-Med in 2004 and led the development of the Nimbus technology used in the Bioguard line of products licensed to Derma Sciences. He has been involved in all aspects of commercializing Quick-Med’s antimicrobial technologies, including biochemistry, biosafety, regulatory and production development. Dr. Liesenfeld also led the Quick-Med team that received the top industrial research prize at the 2011 Wound Healing Society meeting for U.S. Army-sponsored research that showed improved wound healing in an animal model of vesicant injury using an advanced multi-feature Nimbus dressing. Dr. Liesenfeld received a Ph.D. in materials science and engineering from the University of Florida and a bachelor’s degree in mechanical engineering and management from the University of Vermont. Profile
TWST: Could we begin with a brief overview of Quick-Med’s business?
Dr. Liesenfeld: Quick-Med Technologies is a small life sciences company that develops technologies mainly